PE74399A1 - Combinaciones para diabetes de sulfonilurea - glitazona - Google Patents

Combinaciones para diabetes de sulfonilurea - glitazona

Info

Publication number
PE74399A1
PE74399A1 PE1998000113A PE00011398A PE74399A1 PE 74399 A1 PE74399 A1 PE 74399A1 PE 1998000113 A PE1998000113 A PE 1998000113A PE 00011398 A PE00011398 A PE 00011398A PE 74399 A1 PE74399 A1 PE 74399A1
Authority
PE
Peru
Prior art keywords
acid
sulfonilurea
glitazone
combinations
acil
Prior art date
Application number
PE1998000113A
Other languages
English (en)
Inventor
Randall W Whitcomb
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE74399A1 publication Critical patent/PE74399A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMBINACIONES DE COMPUESTOS ANTIDIABETICOS DE SULFONILUREA CON COMPUESTOS DE GLITAZONA PARA MEJORAR EL CONTROL GLUCEMICO. LA SULFONILUREA SE SELECCIONA DE: GLISOXEPIDO, GLIBURIDA, ACETOHEXAMIDA, CLOROPROPAMIDA, GLIBORNURIDA, TOLBUTAMIDA, TOLAZAMIDA, GLIPIZIDA, GLICLAZIDA, GLIQUIDONA, GLIHEXAMIDA, FENBUTAMIDA Y TOLCICLAMIDA. EL AGENTE ANTIDIABETICO DE GLITAZONA TIENE LA FORMULA I, DONDE R1 Y R2 PUEDEN SER H o ALQUILO C1-C5, R3 ES H o UN GRUPO ACILO C1-C6 ALIFATICO, ACILO ALICICLICO, ACILO AROMATICO, ACILO HETEROCICLICO, ACILOARALIFATICO, CARBONILO (ALCOXI C1-C6) O UN GRUPO ARALQUILOXICARBONILO, R4 Y R5 PUEDEN SER H, ALQUILO C1-C5, ALCOXI C1-C5, R4 Y R5 JUNTOS SON ALQUILENODIOXI C1-C4, W ES -CH2-, CO o CHOR6, DONDE R6 ES CUALQUIERA DE LOS GRUPOS DEFINIDOS PARA R3 Y PUEDE SER IGUAL O DIFERENTE A R3, n ES 1, 2, o 3, Y Y Z SON INDEPENDIENTEMENTE O o NH; LAS GLITAZONAS PREFERIDAS SON: LA TROGLITAZONA, CIGLITAZONA, PIOGLITAZONA, ENGLITAZONA, TA 174 Y BRL 49653 (ROSIGLITAZONA)
PE1998000113A 1997-02-19 1998-02-18 Combinaciones para diabetes de sulfonilurea - glitazona PE74399A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19

Publications (1)

Publication Number Publication Date
PE74399A1 true PE74399A1 (es) 1999-08-20

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000113A PE74399A1 (es) 1997-02-19 1998-02-18 Combinaciones para diabetes de sulfonilurea - glitazona

Country Status (29)

Country Link
US (2) US5859037A (es)
EP (1) EP0957923A1 (es)
JP (1) JP2001512478A (es)
KR (1) KR20000071179A (es)
CN (1) CN1244801A (es)
AR (1) AR011829A1 (es)
AU (1) AU741215B2 (es)
BG (1) BG103671A (es)
BR (1) BR9714505A (es)
CA (1) CA2272478A1 (es)
CZ (1) CZ289299A3 (es)
EA (1) EA199900725A1 (es)
EE (1) EE9900345A (es)
GT (1) GT199800037A (es)
HN (1) HN1997000167A (es)
HU (1) HUP0001528A3 (es)
IL (1) IL130027A (es)
IS (1) IS5058A (es)
NO (1) NO993982L (es)
NZ (1) NZ336002A (es)
PA (1) PA8447401A1 (es)
PE (1) PE74399A1 (es)
PL (1) PL335166A1 (es)
SK (1) SK111899A3 (es)
SV (1) SV1998000010A (es)
TR (1) TR199902033T2 (es)
UY (1) UY24893A1 (es)
WO (1) WO1998036755A1 (es)
ZA (1) ZA981343B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
NZ501163A (en) * 1997-06-18 2002-02-01 Smithkline Beecham P Treatment of diabetes with thiazolidinedione and sulphonylurea (glibenclamide, glipizide, gliclazide, glimepiride, tolazamide and tolbutamide
BR9810172A (pt) * 1997-06-18 2000-08-08 Smithkline Beecham Plc Tratamento de diabete com tiazolidinadiona e metformina
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6417185B1 (en) 1998-06-19 2002-07-09 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
KR100689943B1 (ko) * 1998-12-24 2007-03-08 메타베이시스 테라퓨틱스, 인크. 당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
CA2367955C (en) * 1999-03-15 2009-05-19 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
DK1145717T3 (da) 2000-04-13 2004-08-02 Pfizer Prod Inc Synergistisk virkning af glyburid og milrinon
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
ES2529180T3 (es) 2002-09-20 2015-02-17 Andrx Labs Llc Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
WO2005041962A1 (en) 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
TW200722088A (en) * 2005-05-27 2007-06-16 Sankyo Co Diabetes remedy
AU2006289259A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
US20090170762A1 (en) * 2005-09-08 2009-07-02 Uutech Limited Treatment of Diabetes Related Obesity
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
CA2633149C (en) 2005-12-22 2015-06-30 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
PT2868315T (pt) 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
KR20200022525A (ko) * 2008-12-04 2020-03-03 충시 위 고투과력을 가진 조성물 및 이의 적용
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
WO2011059053A1 (ja) * 2009-11-13 2011-05-19 東レ株式会社 糖尿病の治療または予防薬
CN103025334B (zh) 2010-05-24 2016-03-16 澳星医疗私人有限公司 抗糖尿病组合物和方法
KR102072322B1 (ko) 2011-01-19 2020-02-03 프랙틸 래브러토리스 인코포레이티드 조직의 치료를 위한 장치 및 방법
CN104244958B (zh) 2011-11-23 2017-11-17 澳星医疗私人有限公司 改进的协同抗糖尿病组合物
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
WO2015077571A1 (en) 2013-11-22 2015-05-28 Fractyl Laboratories, Inc. Systems, devices and methods for the creation of a therapeutic restriction in the gastrointestinal tract
KR102086184B1 (ko) 2012-02-27 2020-03-06 프랙틸 래브러토리스 인코포레이티드 조직의 치료를 위한 열 절제 시스템，장치 및 방법
KR102231179B1 (ko) 2012-04-19 2021-03-22 프랙틸 래브러토리스 인코포레이티드 조직 팽창 디바이스들, 시스템들, 및 방법들
EP2879605A4 (en) 2012-07-30 2016-04-06 Fractyl Lab Inc ELECTRICITY CONTROL SYSTEMS, DEVICES AND METHOD FOR TREATMENT OF TISSUE
EP2882362B1 (en) 2012-08-09 2024-01-03 Fractyl Health, Inc. Ablation systems, devices and methods for the treatment of tissue
WO2014055997A1 (en) 2012-10-05 2014-04-10 Fractyl Laboratories Inc. Methods, systems and devices for performing multiple treatments on a patient
WO2014197632A2 (en) 2013-06-04 2014-12-11 Fractyl Laboratories, Inc. Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
US11986235B2 (en) 2013-09-12 2024-05-21 Fractyl Health, Inc. Systems, methods and devices for treatment of target tissue
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US9757535B2 (en) 2014-07-16 2017-09-12 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
WO2016011269A1 (en) * 2014-07-16 2016-01-21 Fractyl Laboratories, Inc. Methods and systems for treating diabetes and related diseases and disorders
KR20240024362A (ko) 2014-10-24 2024-02-23 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
US20230139684A1 (en) * 2019-11-22 2023-05-04 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NO318765B1 (no) * 1995-07-03 2005-05-02 Sankyo Co Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
AU5590898A (en) 1998-09-09
PL335166A1 (en) 2000-04-10
US5972973A (en) 1999-10-26
ZA981343B (en) 1998-11-16
BR9714505A (pt) 2000-03-21
CA2272478A1 (en) 1998-08-27
IL130027A0 (en) 2000-02-29
EP0957923A1 (en) 1999-11-24
EA199900725A1 (ru) 2000-04-24
TR199902033T2 (xx) 2000-02-21
US5859037A (en) 1999-01-12
JP2001512478A (ja) 2001-08-21
SK111899A3 (en) 2000-09-12
IS5058A (is) 1999-05-27
UY24893A1 (es) 1998-07-10
NZ336002A (en) 2002-03-28
AU741215B2 (en) 2001-11-29
PA8447401A1 (es) 2001-12-14
KR20000071179A (ko) 2000-11-25
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28
AR011829A1 (es) 2000-09-13
BG103671A (en) 2000-04-28
NO993982D0 (no) 1999-08-18
CZ289299A3 (cs) 1999-11-17
HN1997000167A (es) 1999-02-09
NO993982L (no) 1999-08-18
SV1998000010A (es) 1999-02-02
EE9900345A (et) 2000-02-15
HUP0001528A3 (en) 2000-12-28
IL130027A (en) 2005-09-25
CN1244801A (zh) 2000-02-16
WO1998036755A1 (en) 1998-08-27

Similar Documents

Publication Publication Date Title
PE74399A1 (es) Combinaciones para diabetes de sulfonilurea - glitazona
DK0659174T3 (da) Derivater af valproinsyre og 2-valproensyreamider samt deres anvendelse som antikonvulsive midler
ATE277012T1 (de) Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress
EP1134214A4 (en) PICOLINAMIDE DERIVATIVES AND PESTICIDES CONTAINING THESE DERIVATIVES AS ACTIVE INGREDIENT
NO179142C (no) 3-benzyliden-1-karbamoyl-2-pyrrolidon-analoger
DK0842661T3 (da) Anvendelse af estrogenagonister og -antagonister til fremstilling af et lægemiddel til behandling af atherosclerose, uafhængigt af lipidsænkning
EA200000826A1 (ru) Галоидированные производные амидиноаминокислот, применимые в качестве ингибиторов no-синтазы
DK1114076T3 (da) Acceleratorer til hærdbare systemer
DE3752015D1 (de) Durch Aromaten substituiertes Glykosid
EP0787720A4 (en) NEW PYRIDONE CARBOXYLATE DERIVATIVES OR SALTS THEREOF AND ANTIBACTERIAL COMPOSITIONS THAT CONTAIN THEM AS ACTIVE INGREDIENTS
DK0732928T3 (da) Fremgangsmåde til sænkning af serumcholesterolnuiveauer med 2,6-di-alkyl-4-silyl-phenoler
EP0802191A4 (en) PYRAZOLE DERIVATIVES AND INSECTICIDE COMPOSITIONS CONTAINING SUCH DERIVATIVES AS ACTIVE INGREDIENTS
EP1000923A4 (en) CYCLOPENTEN DERIVATIVES
YU14601A (sh) Tiazolilcinamonitrili i sredstva za suzbijanje štetočina
EP0533933A4 (en) Bisheterocyclic compound
DK0676399T3 (da) Methotrexaderivater
ATE167664T1 (de) Verwendung von aminen in ölzusammensetzungen
MX9605994A (es) Formilaminofenilsulfonilureas, metodos para prepararlos y su uso como herbicidas y reguladores de crecimiento de la plantas.
EP0987257A4 (en) 1,2,3-THIADIAZOLE DERIVATIVES, MEANS FOR CONTROLLING PLANT DISEASES AND METHOD FOR THEIR USE
ES2156099T1 (es) Metodo para tratar sustratos metalicos usando polieteres derivados de mannich.
ES2106199T3 (es) Derivado de nitroxialquilamida.
BR9507857A (pt) Um processo para a preparação de derivados de 5,6-Diidroxi-2-amino-1,2,3,4-tetraidronaftaleno
GB2245566A (en) Carbamoyl derivatives of alkanolamines and antistress-action agent for plant-growth regulation based thereon
CO4940468A1 (es) Nuevos derivados de naftilpiperacina
ATE95172T1 (de) Cyclopropanthiocarbonsaeureamide.

Legal Events

Date Code Title Description
FC Refusal